Waage Anne, Khan Ammar, Labori Knut Jørgen, Birkeland Kåre Inge, Scholz Hanne, Jensen Trond Geir, Tholfsen Tore, Line Pål-Dag, Hagness Morten
Department of Hepato-Pancreato-Biliary Surgery Oslo University Hospital, Rikshospitalet 0372 Oslo Norway.
Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Scand J Surg. 2025 Jun;114(2):174-182. doi: 10.1177/14574969241298985. Epub 2024 Nov 18.
Tailoring surgical treatment is mandatory to optimize outcomes in chronic pancreatitis. Total pancreatectomy (TP) offers pain relief in a subset of patients. TP with islet autotransplantation (IAT) has the potential to reduce the burden of postsurgical diabetes. We present the first Scandinavian prospective study assessing outcomes following total pancreatectomy and islet autotransplantation (TPIAT) in chronic pancreatitis. Our aim was to assess short- and long-term outcomes following implementation of a nationwide program of TPIAT at a tertiary reference center for pancreatic surgery in Norway.
A prospective, observational single-center study enrolling consecutive patients undergoing TPIAT for chronic pancreatitis at Oslo University Hospital. The selection of potential candidates for TPIAT was based on discussions at multidisciplinary team (MDT) meetings, focusing on tailored surgery in chronic pancreatitis. Patients were finally evaluated in a dedicated TPIAT team. The outcome measures included pain relief, quality of life (QoL) assessed by EORTC QLQ-C30, complications, and glycemic control.
Between August 2017 and November 2022, 15 patients underwent TPIAT. The follow-up rate was 87% with a median follow-up of 26 months (range = 14-65). Pain relief was achieved in 92%. EORTC QLQ-C30 analysis revealed clinically significant improvements in 28 of 30 domains, particularly in pain and role- and social-functioning. The Clavien-Dindo ≥IIIa complications occurred in one patient. There was no 90 days mortality. All patients maintained C-peptide positivity, although none of the patients reached insulin independence.
TPIAT was as a safe and effective treatment for a selected group of patients with chronic pancreatitis, providing substantial pain relief and enhanced QoL. Islet autotransplantation prevented complete insulin deficiency, reducing diabetes severity postpancreatectomy. Dedicated chronic pancreatitis MDT meetings were key factor in the success of the program.
为优化慢性胰腺炎的治疗效果,必须进行个体化手术治疗。全胰切除术(TP)能使部分患者的疼痛得到缓解。全胰切除术联合胰岛自体移植(IAT)有可能减轻术后糖尿病的负担。我们开展了第一项斯堪的纳维亚前瞻性研究,评估慢性胰腺炎患者接受全胰切除术和胰岛自体移植(TPIAT)后的疗效。我们的目的是评估挪威一家胰腺手术三级参考中心实施全国性TPIAT项目后的短期和长期疗效。
一项前瞻性、观察性单中心研究,纳入在奥斯陆大学医院接受TPIAT治疗慢性胰腺炎的连续患者。TPIAT潜在候选者的选择基于多学科团队(MDT)会议的讨论,重点是慢性胰腺炎的个体化手术。患者最终由专门的TPIAT团队进行评估。疗效指标包括疼痛缓解情况、通过欧洲癌症研究与治疗组织QLQ-C30问卷评估的生活质量(QoL)、并发症以及血糖控制情况。
2017年8月至2022年11月期间,15例患者接受了TPIAT。随访率为87%,中位随访时间为26个月(范围=14-65个月)。92%的患者疼痛得到缓解。欧洲癌症研究与治疗组织QLQ-C30分析显示,30个领域中有28个领域在临床上有显著改善,尤其是在疼痛以及角色和社会功能方面。1例患者发生Clavien-Dindo≥IIIa级并发症。无90天死亡率。所有患者均保持C肽阳性,尽管没有患者实现胰岛素自主。
TPIAT是治疗特定慢性胰腺炎患者群体的一种安全有效的方法,能显著缓解疼痛并提高生活质量。胰岛自体移植可防止完全胰岛素缺乏,减轻胰腺切除术后糖尿病的严重程度。专门的慢性胰腺炎MDT会议是该项目成功的关键因素。